| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
1 Department of Dermatology, Heinrich-Heine University, Düsseldorf, Germany and 2 Institute of Pathology, Ruhr University, Bochum, Germany
Requests for reprints: Ulrich R. Hengge, Department of Dermatology, Heinrich-Heine University, Moorenstrasse 5, D-40225 Düsseldorf, Germany. Phone: 49-211-811-8066; Fax: 49-211-811-8830; E-mail: ulrich.hengge{at}uni-duesseldorf.de.
Phosphatase and tensin homologue deleted from chromosome 10 (PTEN) seems to be an important tumor suppressor gene in melanoma. Because the PTEN gene is only infrequently deleted or mutated, and because the PTEN protein is low to absent in a significant number of melanomas, we investigated alternative methods of epigenetic silencing. We did quantitative positional methylation analysis (pyrosequencing) on 37 sera from melanoma patients and on 21 pairs of corresponding sera and melanoma specimens in addition to Taqman reverse transcription-PCR. We report significant positional PTEN promoter methylation in 62% of circulating DNA isolated from sera of patients with metastatic melanoma. The percentage of methylation of a selected CpG island in blood showed a correlation with methylation levels in the corresponding melanoma tissue. Moreover, high percentages of PTEN methylation were associated with low PTEN transcription levels. Using the demethylation agent 5-aza-2'-deoxycytidine, reduced methylation and a corresponding increase in PTEN protein were observed in BLM melanoma cells, leading to reduced AKT activity in an in vitro kinase assay. In summary, epigenetic PTEN silencing seems to be a relevant mechanism of inactivating this tumor suppressor gene in melanoma that may promote melanoma development by derepression of the AKT pathway. (Cancer Res 2006; 66(13); 6546-52)
This article has been cited by other articles:
|
|
 |
|
  M. A. Davies, K. Stemke-Hale, E. Lin, C. Tellez, W. Deng, Y. N. Gopal, S. E. Woodman, T. C. Calderone, Z. Ju, A. J. Lazar, et al. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma Clin. Cancer Res., December 15, 2009; 15(24): 7538 - 7546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, J. J. DiGiovanna, J. B. Stern, T. J. Hornyak, M. Raffeld, S. G. Khan, K.-S. Oh, M. C. Hollander, P. A. Dennis, and K. H. Kraemer Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas PNAS, April 14, 2009; 106(15): 6279 - 6284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hino, H. Uozaki, N. Murakami, T. Ushiku, A. Shinozaki, S. Ishikawa, T. Morikawa, T. Nakaya, T. Sakatani, K. Takada, et al. Activation of DNA Methyltransferase 1 by EBV Latent Membrane Protein 2A Leads to Promoter Hypermethylation of PTEN Gene in Gastric Carcinoma Cancer Res., April 1, 2009; 69(7): 2766 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tang and E. Goldberg Homo sapiens Lactate Dehydrogenase c (Ldhc) Gene Expression in Cancer Cells Is Regulated by Transcription Factor Sp1, CREB, and CpG Island Methylation J Androl, March 1, 2009; 30(2): 157 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhu, A. Wloch, Q. Wu, C. Peters, A. Pagenstecher, H. Bertalanffy, and U. Sure Involvement of PTEN Promoter Methylation in Cerebral Cavernous Malformations Stroke, March 1, 2009; 40(3): 820 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zheng, L. Gao, Y. Feng, L. Yuan, H. Zhao, and L. A. Cornelius Down-regulation of Rap1GAP via Promoter Hypermethylation Promotes Melanoma Cell Proliferation, Survival, and Migration Cancer Res., January 15, 2009; 69(2): 449 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Holtkamp, E. Malzer, J. Zietsch, A. F. Okuducu, J. Mucha, C. Mawrin, V.-F. Mautner, H.-U. Schildhaus, and A. von Deimling EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy Neuro Oncology, December 1, 2008; 10(6): 946 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Lo and O. N. Witte Transforming Growth Factor-{beta} Activation Promotes Genetic Context-Dependent Invasion of Immortalized Melanocytes Cancer Res., June 1, 2008; 68(11): 4248 - 4257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tamguney and D. Stokoe New insights into PTEN J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dejeux, V. Audard, C. Cavard, I. G. Gut, B. Terris, and J. Tost Rapid Identification of Promoter Hypermethylation in Hepatocellular Carcinoma by Pyrosequencing of Etiologically Homogeneous Sample Pools J. Mol. Diagn., September 1, 2007; 9(4): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Tischoff, U R Hengge, M Vieth, C Ell, M Stolte, A Weber, W E Schmidt, and A Tannapfel Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma Gut, August 1, 2007; 56(8): 1047 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Wiencke, S. Zheng, N. Jelluma, T. Tihan, S. Vandenberg, T. Tamguney, R. Baumber, R. Parsons, K. R. Lamborn, M. S. Berger, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma Neuro Oncology, July 1, 2007; 9(3): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Fecher, S. D. Cummings, M. J. Keefe, and R. M. Alani Toward a Molecular Classification of Melanoma J. Clin. Oncol., April 20, 2007; 25(12): 1606 - 1620. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
